FAK inhibitor

DRUG CLASS:

FAK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

KRAS wild-type	Ovarian Cancer	KRAS wild-type	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B	IN10018 Sensitive: B - Late Trials IN10018 Sensitive : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Mesothelioma	ALK positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3	MRTX1257 + IN10018 Sensitive: C3 – Early Trials MRTX1257 + IN10018 Sensitive : C3
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
NF2 mutation	Meningioma	NF2 mutation	Meningioma	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D	sotorasib + IN10018 Sensitive: D – Preclinical sotorasib + IN10018 Sensitive : D
SRC T341I	Cholangiocarcinoma	SRC T341I	Cholangiocarcinoma	AZD0530 Resistant: D – Preclinical AZD0530 Resistant : D	AZD0530 Resistant: D – Preclinical AZD0530 Resistant : D
KRAS G12D	Cholangiocarcinoma	KRAS G12D	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH2 R172K	Cholangiocarcinoma	IDH2 R172K	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
IDH2 mutation	Cholangiocarcinoma	IDH2 mutation	Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
NF2 expression	Ovarian Cancer	NF2 expression	Ovarian Cancer	PF-562271 Sensitive: D – Preclinical PF-562271 Sensitive : D	PF-562271 Sensitive: D – Preclinical PF-562271 Sensitive : D
NF2 negative	Triple Negative Breast Cancer	NF2 negative	Triple Negative Breast Cancer	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D	VS-4718 Sensitive: D – Preclinical VS-4718 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
TP53 mutation	Colorectal Cancer	TP53 mutation	Colorectal Cancer	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR H1968Y	Melanoma	MTOR H1968Y	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR P2213S	Melanoma	MTOR P2213S	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
MTOR S2215Y	Melanoma	MTOR S2215Y	Melanoma	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D	LY294002 Sensitive: D – Preclinical LY294002 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D
EGFR amplification	Oral Cancer	EGFR amplification	Oral Cancer	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D	AZD0530 Sensitive: D – Preclinical AZD0530 Sensitive : D
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D	talazoparib + LY294002 Sensitive: D – Preclinical talazoparib + LY294002 Sensitive : D

FAK inhibitor

FAK inhibitor

Associations(38)

Associations
(38)